Following on from the success of brentuximab vedotin, new antibody-drug conjugates (ADCs) for lymphoma are on the horizon. These successors utilize novel technologies, such as those that allow the determination of how many drugs are attached to the antibody, as well as more potent toxins. In this interview, Graham Collins, MRCP, FRCPath, DPhil, of Oxford University Hospitals NHS Foundation Trust, Oxford, UK, provides an overview of the Phase I study of ADCT-301 for relapsed or refractory Hodgkin and non-Hodgkin lymphoma (NCT02432235). Dr Collins discusses the differences between ADCT-301 and other ADCs, the very promising response rates seen in the trial and toxicities. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
New antibody-drug conjugates for lymphoma
